RISPERDAL® CONSTA® (risperidone) Long Acting Injection

Understanding Schizophrenia
Treatment of Schizophrenia
Importance of Staying on Treatment
RISPERDAL CONSTA: A Different Option
The Mental Healthcare Team
Recognizing the Signs of Relapse
Psychosocial Treatment, Rehabilitation and Support
Taking Care of Yourself
News Center
Resources
For Patients
For Healthcare Providers
También en Español
Full US Prescribing Information
Sitemap
Global Resources
Tell a friend
Privacy Policy
Legal Notice
Printer Friendly
 Text Size:  S | M |  L
 
 
 
    


For Caregivers

The greatest factor influencing whether or not patients with schizophrenia stay on medication is family and social support.

Schizophrenia doesn't just affect individuals, but entire families. Very often a family member becomes the primary caregiver to a loved one with schizophrenia. Your role in supporting and encouraging your loved one is of paramount importance to their improvement . As devastating a diagnosis of schizophrenia may seem, there is hope. Research shows that patients with caregiver support tend to have fewer relapse episodes and a more profound improvement . With treatment, counseling and support, many people with schizophrenia can develop the skills they need to live full, productive and independent lives.

The information in this section is designed to help you, the caregiver provide the best possible care to your friend or relative with schizophrenia.

<Back to Top>



       

 


RISPERDAL® CONSTA® (risperidone) is used for the treatment of schizophrenia.

IMPORTANT SAFETY INFORMATION FOR RISPERDAL® CONSTA®

Elderly Patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. RISPERDAL® CONSTA® (risperidone) is not approved for the treatment of patients with dementia-related psychosis.

Neuroleptic Malignant Syndrome (NMS) is a rare and potentially fatal side effect reported with RISPERDAL® CONSTA® and similar medicines. Call your doctor immediately if the person being treated develops symptoms such as high fever; stiff muscles; shaking; confusion; sweating; changes in pulse, heart rate, or blood pressure; or muscle pain and weakness. Treatment should be stopped if the person being treated has NMS.

Tardive Dyskinesia (TD) is a serious, sometimes permanent side effect reported with RISPERDAL® CONSTA® and similar medications. TD includes uncontrollable movements of the face, tongue, and other parts of the body. The risk of developing TD and the chance that it will become permanent is thought to increase with the length of therapy and the overall dose taken by the patient. This condition can develop after a brief period of therapy at low doses, although this is much less common. There is no known treatment for TD, but it may go away partially or completely if therapy is stopped.

High blood sugar and diabetes have been reported with RISPERDAL® CONSTA® and similar medications. If the person being treated has diabetes or risk factors such as being overweight or a family history of diabetes, blood sugar testing should be performed at the beginning and throughout treatment with RISPERDAL® CONSTA®. Complications of diabetes can be serious and even life threatening. If signs of high blood sugar or diabetes develop, such as being thirsty all the time, going to the bathroom a lot, or feeling weak or hungry, contact your doctor.

RISPERDAL® CONSTA® and similar medications can raise the blood levels of a hormone known as prolactin, causing a condition known as hyperprolactinemia. Blood levels of prolactin remain elevated with continued use. Some side effects seen with these medications include the absence of a menstrual period; breasts producing milk; the development of breasts by males; and the inability to achieve an erection. The connection between prolactin levels and side effects is unknown.

Some people taking RISPERDAL® CONSTA® may feel faint or lightheaded when they stand up or sit up too quickly. By standing up or sitting up slowly and following your healthcare professional's dosing instructions, this side effect can be reduced or it may go away over time.

RISPERDAL® CONSTA® may affect your alertness or driving ability; therefore, do not drive or operate machinery before talking to your healthcare professional.

RISPERDAL® CONSTA® should be used cautiously in people with a seizure disorder, who have had seizures in the past, or who have conditions that increase their risk for seizures.

Extrapyramidal Symptoms (EPS) are usually persistent movement disorders or muscle disturbances, such as restlessness, tremors, and muscle stiffness. If you observe any of these symptoms, talk to your healthcare professional.

Inform your healthcare professional if you become pregnant or intend to become pregnant during therapy with RISPERDAL® CONSTA®. Caution should be exercised when RISPERDAL® CONSTA® is administered to a nursing woman.

RISPERDAL® CONSTA® may make you more sensitive to heat. You may have trouble cooling off, or be more likely to become dehydrated, so take care when exercising or when doing things that make you warm.

Some medications interact with RISPERDAL® CONSTA®. Please inform your healthcare professional of any medications or supplements that you are taking. Avoid alcohol while on RISPERDAL® CONSTA®.

In a study of people taking RISPERDAL® CONSTA®, the most common side effects in the treatment of schizophrenia were headache, tremors, dizziness, restlessness, tiredness, constipation, indigestion, sleepiness, weight gain, pain in the limbs, and dry mouth.

If you have any questions about RISPERDAL® CONSTA® or your therapy, talk with your doctor.

For more information, read the Important Product Information by clicking here.

01CS1054




Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Home   Janssen.com   Site Map   Contact Us   

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2003 – 2008. This site is published by Janssen®, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents. This site is intended for visitors from the United States.
This page was last updated on: Oct 08 2007 at 14:46:50 EDT